Opening a new pathway
for people with cardiovascular disease
IsomAb is taking a different approach to curing cardiovascular disease – starting with chronic stable angina (CSA) and peripheral arterial disease (PAD).
Cardiovascular disease is the world’s largest cause of death, with over 600 million people globally affected. Most people with cardiovascular disease have insufficient blood flow to one or more parts of their body due to a combination of partially blocked arteries and a lack of alternative vessels (collaterals).
IsomAb’s therapeutic antibody, ISM-001, enhances the body’s own ability to create a biological bypass to supply blood to where it is needed.
In chronic stable angina this means generating a better blood vessel network so that blood can reach parts of the heart fast enough to allow normal function, relieving pain on exercise and reducing the likelihood of a subsequent heart attack.
In peripheral arterial disease it will help blood vessels to grow into areas where no oxygen can reach, allowing ulcers to heal faster, reducing pain at rest and helping people walk more easily.
ISM-001 works by specifically inhibiting the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A). This form of VEGF puts the brakes on new blood vessel growth and is turned on in people with cardiovascular diseases. ISM-001 takes the brakes off, allowing blood vessels to grow, remodel and make new arteries.
660 Million Cardiovascular Patients Worldwide
